Grifols | GRFS - Current Assets


Grifols reported EUR5.96B in Current Assets for its fiscal quarter ending in December of 2025.





Current Assets Change Date
Alaunos Therapeutics USD 2.68M 1.05M Sep/2025
Arca Biopharma USD 343.86M 11.31M Dec/2025
aTyr Pharma USD 245.8M 152.79M Dec/2025
Bio Path USD 663K 17K Sep/2025
Brainstorm Cell Therapeutics USD 307K 201K Dec/2025
Capricor Therapeutics USD 322.94M 221.99M Dec/2025
Cara Therapeutics USD 38.44M 4.69M Sep/2025
Esperion Therapeutics USD 462.57M 102.11M Dec/2025
GlaxoSmithKline GBP 17.51B 332M Dec/2025
Grifols EUR 5.96B 316.31M Dec/2025
Immunic USD 39.27M 20.57M Sep/2025
Infinity Pharmaceuticals USD 19.91M 8.46M Jun/2023
Minerva Neurosciences USD 83.1M 70.08M Dec/2025
Nektar Therapeutics USD 266.27M 15.09M Dec/2025
Sangamo BioSciences USD 49.89M 12.3M Jun/2025
TherapeuticsMD USD 11.82M 303K Jun/2024